Guggenheim Increases Eli Lilly and Company (NYSE:LLY) Price Target to $1,168.00

Eli Lilly and Company (NYSE:LLY) had its target price raised by equities researchers at Guggenheim from $1,161.00 to $1,168.00 in a report released on Thursday,MarketScreener reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s target price would suggest a potential upside of 14.90% from the stock’s current price.

A number of other equities analysts also recently weighed in on the stock. Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a report on Thursday, February 19th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Truist Financial reissued a “buy” rating on shares of Eli Lilly and Company in a report on Monday. Deutsche Bank Aktiengesellschaft boosted their target price on Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, Wolfe Research boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,229.59.

Eli Lilly and Company Trading Down 1.2%

Shares of Eli Lilly and Company stock traded down $12.34 during midday trading on Thursday, reaching $1,016.49. The company had a trading volume of 315,059 shares, compared to its average volume of 3,285,420. The firm has a market cap of $958.92 billion, a PE ratio of 44.30, a P/E/G ratio of 1.21 and a beta of 0.39. The stock has a fifty day moving average price of $1,054.25 and a 200 day moving average price of $924.46. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same period last year, the business earned $5.32 EPS. Eli Lilly and Company’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after acquiring an additional 1,006,885 shares during the period. State Street Corp grew its position in Eli Lilly and Company by 1.8% in the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after acquiring an additional 635,358 shares during the period. Capital Research Global Investors increased its position in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. Morgan Stanley raised its stake in shares of Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after acquiring an additional 407,166 shares during the last quarter. Finally, Capital World Investors boosted its stake in Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after purchasing an additional 61,851 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: ACHIEVE‑3 Lancet results: orforglipron showed superior A1C reduction and greater weight loss vs. oral semaglutide (36 mg vs 14 mg), and Lilly says it has submitted the drug to regulators in 40+ countries with potential U.S. obesity action in Q2 2026 — a major revenue catalyst if approved. Lilly press release / Lancet publication
• Positive Sentiment: Analyst initiation: RBC started coverage on LLY with an “Outperform” and $1,250 price target, signaling street confidence and potential upside versus the current price. RBC / StreetInsider
• Positive Sentiment: Other clinical wins: positive Phase 3 open‑label extension data for Omvoh (mirikizumab) and the broader GLP‑1 franchise momentum (Mounjaro/Zepbound) support the company’s revenue growth outlook and FY guidance. Yahoo / VIVID‑2 extension
• Neutral Sentiment: Additional safety detail released: Reuters published more granular side‑effect data from the orforglipron vs. oral semaglutide diabetes trial — useful for regulators and investors but not an immediate approval blocker; would be watched closely by risk‑averse holders. Reuters: additional side‑effect data
• Neutral Sentiment: Street commentary on competitive pricing: BofA and other banks say Novo Nordisk’s announced list‑price cuts may not materially change U.S. market dynamics for GLP‑1s, which tempers downside risk from pricing moves. Yahoo / BofA note
• Negative Sentiment: Novo price cuts & market reaction: Novo’s plan to slash U.S. list prices for Ozempic/Wegovy (reported broadly) has pressured biotech/GLP‑1 names and contributed to recent pulls in LLY shares as investors debate margin and competitive impact. This remains the main near‑term risk to sentiment. Yahoo: Novo halves US price

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.